Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969439 | 0.79 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1MAPTNPC1PKM | |
| SCHEMBL31305639 | 0.79 | L3MBTL1 (0.83) | L3MBTL1ALDH1A1MAPTNPC1PKM | |
| SCHEMBL5774366 | 0.76 | HSP90AA1 (0.55) | HSP90AA1L3MBTL1ALDH1A1MAPTNPC1 | |
| SCHEMBL18228118 | 0.76 | L3MBTL1 (0.86) | L3MBTL1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL3390298 | 0.76 | L3MBTL1 (0.86) | L3MBTL1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL3973786 | 0.75 | CYP3A4 (0.42) | HSP90AA1KDM4EMAPTSMN1; SMN2ADRA1A | |
| SCHEMBL22056133 | 0.74 | HSP90AA1 (1.00) | HSP90AA1ALDH1A1KDM4EHTTRAB9A | |
| SCHEMBL10743351 | 0.74 | HSP90AA1 (0.73) | HSP90AA1L3MBTL1ALDH1A1KDM4ENPC1 | |
| SCHEMBL9320858 | 0.74 | HSP90AA1 (1.00) | HSP90AA1ALDH1A1KDM4EHTTRAB9A | |
| SCHEMBL10746315 | 0.74 | HSP90AA1 (0.73) | HSP90AA1L3MBTL1ALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2023-05-04 | — | — | US | disclosed |
| US-20230049917-A1 | Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof | LUPIN LIMITED (IN) | 2023-02-16 | — | — | US | disclosed |
| WO-2021144814-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021130779-A1 | PHARMACEUTICAL COMPOSITION OF CASR MODULATORS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2511257-B1 | Composition comprising an alpha ketoamide compound as cysteine protease inhibitor | VIROBAY INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-8518874-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8450373-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1865940-B1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2511257-A2 | Alpha ketoamide compounds as cysteine protease inhibitors | ViroBay, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1865940-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Applera Corporation (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2006102243-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | CASR, CALCR, RYR1 | HSP90AA1 4637/4885L3MBTL1 4452/4885ALDH1A1 2602/4885 |
| US-20080161254-A1 | HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | HSP90AA1 1365/4885L3MBTL1 4220/4885ALDH1A1 1800/4885 |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | HSP90AA1 596/4885L3MBTL1 1488/4885ALDH1A1 2023/4885 |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | HSP90AA1 596/4885L3MBTL1 1488/4885ALDH1A1 2023/4885 |
| US-20230049917-A1 | Pharmaceutical Composition of CASR Modulators and Methods and Uses Thereof | CASR, CALCR, PTH1R | HSP90AA1 4366/4885L3MBTL1 4863/4885ALDH1A1 3915/4885 |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | HAVCR2, EIF2AK2, GTF3C1 | HSP90AA1 1528/4885L3MBTL1 3860/4885ALDH1A1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.